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Abstract
The genetic landscape of diseases associated with changes in bone mineral density (BMD),
such as osteoporosis, is only partially understood. Here, we explored data from 3,823
mutant mouse strains for BMD, a measure that is frequently altered in a range of bone
pathologies, including osteoporosis. A total of 200 genes were found to significantly affect
BMD. This pool of BMD genes comprised 141 genes with previously unknown functions in
bone biology and was complementary to pools derived from recent human studies. Nineteen
of the 141 genes also caused skeletal abnormalities. Examination of the BMD genes in oste-
oclasts and osteoblasts underscored BMD pathways, including vesicle transport, in these
cells and together with in silico bone turnover studies resulted in the prioritization of candi-
date genes for further investigation. Overall, the results add novel pathophysiological and
molecular insight into bone health and disease.
Author summary
Patients affected by osteoporosis frequently present with decreased BMD and increased
fracture risk. Genes are known to control the onset and progression of bone diseases such
as osteoporosis. Therefore, we aimed to identify osteoporosis-related genes using BMD
measures obtained from a large pool of mutant mice genetically modified for deletion of
individual genes (knockout mice). In a collaborative endeavor involving several research
sites world-wide, we generated and phenotyped 3,823 knockout mice and identified 200
genes which regulated BMD. Of the 200 BMD genes, 141 genes were previously not
known to affect BMD. The discovery and study of novel BMD genes will help to better
understand the causes and therapeutic options for patients with low BMD. In the long
run, this will improve the clinical management of osteoporosis.
Introduction
Osteoporosis is a common disease, characterized by decreased BMD and increased fracture
risk, which causes a profound health burden world-wide [1]. With the discovery that BMD
traits are heritable [2], the interest in identifying associated genes has led to a series of studies
[3–7]. However, only a limited number of osteoporosis-related genes have already been discov-
ered [8], prompting continuing interest in genes controlling BMD. More recently, three
sophisticated genome-wide association studies (GWAS) on osteoporosis and osteoarthritis
genes were reported [9–11]. They demonstrated the power of GWAS for the rapid identifica-
tion of new human genetic loci likely to be associated with osteoporosis. However, the identifi-
cation of the specific genes that cause BMD alterations remained challenging. Both
aforementioned GWAS analyses on osteoporosis relied on the assessment of mouse knockout
models to corroborate the proposed candidate genes [9, 10]. This stressed the value of knock-
out mouse models for the true identification of genes controlling BMD.
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Beyond the assessment of individual knockout mice for data corroboration, a more system-
atic and comprehensive production and skeletal phenotyping of knockout mice has been part
of the IMPC, an international consortium of mouse clinics (Fig 1A) [12–14]. Work at the
IMPC aims to individually ablate the function of every protein-coding gene in mice, and sub-
sequently phenotype the mutated animals [15–18]. The IMPC phenotyping pipeline interro-
gates a range of organ and tissue types, including the skeleton. The skeletal exams encompass
dual-energy X-ray absorptiometry (DXA)-based measures of the three important bone param-
eters bone area (BA), bone mineral content (BMC), and the resulting BMD. Further to this,
planar radiographic images are used for detection of skeletal abnormalities. This study probed
the IMPC data release 6.0 and focused on genes controlling BMD. This measure was selected
because in the clinical setting, in veterinary medicine, and in genetic mouse models low BMD
is a hallmark of osteoporosis [19–21]. The present study has been driven by the following three
research questions: (1) does screening of mutant mice at scale identify novel genes controlling
BMD?, (2) which BMD genes cause both BMD alterations and skeletal abnormalities?, and (3)
is there evidence for functions of novel BMD genes in osteoblasts or osteoclasts? (Fig 1B).
Addressing these questions, we report on a total of 200 BMD genes that, when deleted, caused
alteration in BMD. Of those 200 genes, 59 loci (class 1) had a previously reported function in
bone, while 141 (class 2) genes were not previously described as regulators of BMD in mouse
or human. Using a combination of IMPC phenotyping data with traditional bioinformatics
and an innovative in silico bone turnover model, enabled insight into the biology of BMD
maintenance and identified novel skeletal candidate genes, including Arl4d, Ncald, and
Rab3ip, for further investigation.
Results
Identification and characterization of BMD Genes
Bone mineral density data on 3,823 genes were recorded and analyzed (Fig 1A). Within this
gene set, we identified 200 (5%) genes that caused a statistically significant (p<0.0001)
decrease or increase in BMD when compared to wt control animals (Fig 2A and S1 and S2
Tables. Together, the pool of 200 BMD genes was then analyzed further. A majority, 123
genes, produced a low BMD phenotype, while 64 genes caused a high BMD phenotype (Fig
2B). In addition, 13 genes were associated with either a low or high BMD phenotype, depend-
ing on sex (Figs 2B and S1). Thus, the 200 BMD genes were derived from 213 mutant mouse
lines, of which 161, 47, and 5 were homozygotes, heterozygotes, and hemizygotes, respectively
(S1 Table). The identity of the 200 BMD genes is shown in Table 1 and S1 Table. With the
exception of 4930591A17Rik, biological functions of all BMD genes had been previously
reported to some extent. To determine if novel BMD loci were among the 200 genes, we dis-
criminated between genes with a known (class 1) and unknown (class 2) function in bone biol-
ogy based on previously published data. A total of 59 and 141 genes were assigned to classes 1
(blue) and 2 (yellow), respectively (Table 1).
To quantitatively assess the change in BMD caused by the 200 genes, we plotted gene num-
bers against percentage of change in BMD (Fig 2C). While decreases in BMD ranged from 2%
to 49%, and increases from 2% to 52%, we observed that the majority of genes elicited a reduc-
tion in BMD between 5% and 10%. PhenStat, the statistical package used for the analysis of the
high-throughput phenotype data, did not consider BMD changes between -2% and +2% to be
significant phenotypes. A comparison between male and female animals showed an asymmet-
rical data distribution with about twice as many genes causing a 5% to 10% increased BMD in
males than in females (Fig 2C). Regardless of sex, BMD decreased greater than 20% only upon
deletion for the class 1 genes Lepr, Bbs5, Cyp27b1, and Ghrh, while it increased by more than
PLOS GENETICS Novel genes controlling bone mineral density
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Fig 1. IMPC work-flow and study design. (A) Standardized and automated data flow enabled the large-scale mouse phenotyping under the IMPC
program. Shown is the flow of data from IMPC phenotyping mouse clinics to the IMPC Data Coordination Centre for validation, quality control
(QC) and preliminary analysis. Work at the Data Coordination Center is governed by uniform operating procedures detailed in IMPReSS
(International Mouse Phenotyping Resource of Standardized Screens), while iMits (International Micro-Injection Tracking System) enables efficient
and coordinated mice strain production. The Core Data Archive provides final analysis, prior to data release. Standardization, data quality control, an
automated statistical analysis pipeline, and the phenotyping of reference strains to assess inter-center variation all help ensure robust and reproducible
data. (B) The IMPC skeletal data was investigated. It encompassed primarily BMD measures but also a X-ray-based detection of skeletal
abnormalities. Our investigation was guided by three successive research questions. BMD genes with known and unknown function in bone biology
were categorized as class 1 (blue) and class 2 (yellow) BMD genes, respectively.
https://doi.org/10.1371/journal.pgen.1009190.g001
Fig 2. Mouse phenotyping identified 200 BMD genes. (A) Of the 3,823 genes deleted in mice, 200 or 5% caused a change in BMD phenotype. (B) Directional changes in
BMD. Low and high BMD was found after deletion of 123 and 64 genes, respectively. Another 13 genes caused low or high BMD dependent on sex. (C) Percentage change
in BMD compared to wt animals. In both male (blue bars) and female (pink bars) mice, most BMD genes reduced BMD between 5% and 10%. Changes between -2% and
+2% were not plotted as these were not considered by PhenStat as significant phenotypes. (D) and (E) A limited weight difference compared to wt controls in combination
with a greater than 10% decrease or increase in BMD change prioritized (gray shaded areas) genes for further investigation. Genes with a greater than 10% decrease (D) or
increase (E) in BMD were plotted separately, and genes affecting female or male mice represented individually. Priority genes in the gray shaded areas were colored yellow
or blue according to class 1 or 2, respectively. For clarity, outside the gray sectors, only genes associated with greater than 20% decrease (D) or increases (E) in BMD were
name tagged.
https://doi.org/10.1371/journal.pgen.1009190.g002
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20% only after loss of the class 1 gene Lrrk1 (Fig 2D and 2E and S1 Table). To further prioritize
the BMD genes, we set criteria by asking which class 2 gene deletions resulted in a greater than
10% decrease or increase in BMD in conjunction with a limited weight change. Weight
changes can confound BMD assessments and we set an arbitrary limit to approximately 10%
of the body weight of the animal. The 6 low BMD genes Dhx40, Fancl, Nhlh2, Prdm14, Slc9a4,
and Spata22 (Fig 2D), and the 3 high BMD genes Cd5l, Dppa1, and Vat1l (Fig 2E) met our cri-
teria. Deletion of Nhlh2 and Dppa1 yielded the most pronounced decrease and increase in
BMD, respectively.
To survey for a potential role of the 200 BMD genes in human BMD, GWAS data based on
the UK Biobank release was interrogated. We selected the UK Biobank because we believe the
size of the data set is an advantage that offsets the difference in BMD acquisition technique,
which was based on ultrasound and not the X-ray mean used in this study. A distance range
between 0 kilo bases (kB) and 250 kb was chosen. Of the 200 genes, 11, 38, and 52 genes
matched the human GWAS derived genes at a 0 kB, 100 kB, and 250 kB distance range, respec-
tively (S3 Table). To take a closer look at genes with potential human relevance, we then utilized
the GEFOS data set, which although smaller than the UK Biobank release, utilized X-ray-based
BMD acquisition. The six class 2 genes AP4E1, KIAA0825, ACSF2, PKP4, TTC28, PHF19 and
the class 1 gene MACROD2 altered BMD in humans (S4 Table). The direction of BMD change
matched between mouse and human for the five genes ACSF2, PKP4, TTC28, PHF19 and
MACROD2, and as described below the latter was found to be expressed in osteoblasts.
Sexual dimorphism of the BMD genes
The observation that the direction of BMD change depended on sex in 13 genes prompted fur-
ther investigation of a potential sexual bias in BMD. Of the 13 genes, 11 genes caused low
BMD in females and high BMD in males, and 2 genes produced high BMD in females and low
BMD in males (Fig 3A). We then examined genes causing a unidirectional change in BMD.
Twenty-six, 29, and 68 genes caused low BMD in female, male and both sexes, respectively
(Fig 3B). In comparison, 6, 29, and 29 genes caused high BMD in females, males, and both
sexes, respectively (Fig 3C). A cross-comparison independent of the direction of the BMD
change, demonstrated that a sub-set of 90 genes regulated BMD exclusively in either females
or males. Of those 90 genes, only 11 genes have been previously described in the context of sex-
ual dimorphism in organs other than bone (Fig 3D).
Pleiotropy of the BMD genes
Taking advantage of the broad phenotyping approach of the IMPC, we screened the 200 BMD
































Mouse genes and in parenthesis the human orthologues are presented.
Color: Blue, class 1 genes (known function in bone biology); yellow class 2 genes (unknown function in bone biology): orange (no known function). Shading: Light blue/
yellow, decreased BMD; dark blue/yellow, increased BMD; mixed dark and light, decreased/increased BMD dependent on sex. Abbreviation: N/A, not available.
https://doi.org/10.1371/journal.pgen.1009190.t001
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frequently (99 genes), followed by changes in growth/size/body region (94 genes), behavior/
neurological (92 genes), and adipose tissue (72 genes) (Fig 4A and S5 Table). Next, we deter-
mined the inter-relationships of the co-phenotypes. With the exception of expected relation-
ships, for example between homeostasis/metabolism, adipose tissue and growth/size, we
observed a mostly uniform distribution of phenotype connections (Fig 4A). In contrast, there
was variability in the pleiotropy distribution across the BMD genes. About half of the 200
BMD genes presented with up to 3 co-phenotypes, and only a few genes associated with large
numbers of co-phenotypes (Fig 4B). Importantly, no co-phenotypes were detected for the
eight class 2 genes Ang6, Dnase2b, Frmd7, Mlec, Pfkfb3, Stard5, Tmem42, and Zfp704, sug-
gesting they affected the skeleton specifically. To assess if loss of any of these eight genes or any
other class 2 genes produced gross skeletal abnormalities in addition to their BMD phenotype,
we read the radiographs routinely performed as part of the IMPC phenotyping. None of the
eight class 2 genes had both BMD changes and skeletal abnormalities. However, 19 other class
2 genes caused skeletal abnormalities in addition to changes in BMD (Fig 4C). Vertebrae
abnormalities were the primary skeletal phenotype associated among the BMD genes (Fig 4C)
and were seen in the 9 genes Adnp2, Arhgef4, Dscc1, Fam160a1, Hbs1l, Pex3, Sh3gl2,
Slc25a30, and Slc38a10. As a combination of altered BMD and skeletal abnormality has the
potential to compromise the biomechanical stability of bone, we explored the biomechanical
testing data collected as part of the OBCD project. For this, we facilitated the import of skeletal
phenotyping data from the OBCD into IMPC. Then, we surveyed the bones of the 19 knockout
Fig 3. BMD genes displayed sexual dimorphism. (A-C) A subset of 90 genes affected BMD specifically in one sex. The 90 genes encompass in females (pale pink
bars) 26 low BMD and 6 high BMD genes plus in males (magenta) 29 low BMD and 29 high BMD genes. (D) The identity of all sexually dimorphic genes grouped
by class and direction of BMD change. Genes with a previously reported role in sexual dimorphism other than bone are marked red.
https://doi.org/10.1371/journal.pgen.1009190.g003
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mice for compromised mechanical stability, a functional hallmark of osteoporosis. Of the 19
genes with both a BMD and skeletal phenotypes, the three genes Hbs1l, Slc25a30 and Slc38a10
matched to the OBCD data, but only loss of Hbsl affected skeletal stability, specifically it
resulted in a decrease in vertebrae stiffness and yield load (Fig 4D–4F). This demonstrated a
functional role of Hsb1l in skeletal maintenance and was consistent with the vertebrae abnor-
malities detected by radiographic screening (Fig 4G). Interestingly, loss of Hsb1l also caused
cranio-facial abnormalities (Fig 4G). With the limited overlap between IMPC and OBCD in
Fig 4. BMD genes were pleiotropic. (A) Chord diagram plotting the inter-connectivity of co-phenotypes associated with the 200 BMD genes. The outer segments
represent the co-phenotypes grouped as top-level Mammalian Phenotype (MP) terms. The segment size correlates with the number of genes exhibiting the co-phenotype.
Homeostasis/metabolism was the primary co-phenotype detected. The size of the arcs connecting the phenotypes was proportional to the number of genes connected.
Diagram colors were assigned clockwise starting with the primary phenotype. (B) The majority of BMD genes presented with up to 3 co-phenotypes, while eight genes
were limited to a skeletal phenotype. Class 1 (known function in bone biology) and 2 (unknown function in bone biology) genes are distinguished in yellow and blue
color, respectively. (C) Analysis of the IMPC phenotyping data showed that 19 of the 141 class 2 genes were also associated with skeletal abnormalities in addition to
changes in BMD. Vertebrae abnormalities were the most frequent skeletal abnormalities associated with the deletion of one of the 19 genes. (D) OBCD data showed a
difference in vertebra stiffness for Hbs1l compared to wt. (E) OBCD data detected a difference in vertebra yield load for Hbs1l compared to wt. (F) OBCD data measured a
difference in vertebral height for Hbs1l compared to wt. (G) Dorsal images were taken from the IMPC x-ray screen. Representative female Hbs1l-deficient mice and wild
type (wt) control mice are shown. In the upper panels, the position of the pubic body was denoted by a black line. In Hbs1l-/- mice, a distal shift of the pubic body
intersection relative to the S1 sacral vertebra was seen (p<0.0001 for vertebrae abnormality in the Hbs1l-/- cohort versus wt mice). The two lower panels show a skull close-
up on a second set of female animals. Identical outlines of the cranium were superimposed. Hbs1l-/- mice showed a compressed cranium including nasal bones (p<1x10-8
for vertebrae abnormality in the Hbs1l-/- cohort versus wt mice). (H) Among the 19 genes with both BMD change and skeletal abnormality, a limited weight difference
compared to wt controls and a low number of co-phenotypes (gray shaded area) indicated genes more likely to directly affect the skeleton. All 19 genes were plotted, genes
in the gray shaded areas were colored in yellow according to their class 2 designation.
https://doi.org/10.1371/journal.pgen.1009190.g004
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mind, we pursued another strategy to isolate good candidate genes. A weight change limited to
about 10% and low number of maximal 2 co-phenotypes were used to identify genes more
likely to directly affect the skeleton. The five genes Arl4d, Bbx, Fam160a1, Sdsl, and Tnfaip1
fulfilled these two criteria (Fig 4H).
Function of novel BMD Genes in osteoclasts and osteoblasts
To offer insight into a potential direct role of the 200 BMD genes in bone we focused on the
two principle bone cell types. Using available gene expression data, the 200 genes were
assigned to osteoclasts and osteoblasts (Fig 5A and 5B). We found that of the 200 genes 29 and
16 genes were expressed in osteoclasts and osteoblasts, respectively (p<0.05), with an overlap
in expression seen for Cbk, Ptafr, Satb1, and Sdsl. With respect to the five class 2 genes Arl4d,
Bbx, Fam160a1, Sdsl and Tnfaip1 identified above, Arl4d and Sdsl were expressed in bone
cells. Using STRING, we then tested (p<2.2x10-16) for protein-protein interactions (PPIs)
within the sets of 29 and 16 genes expressed in osteoclasts and osteoblasts, respectively (Fig 5C
and 5D). Upon thresholding, 26 osteoclast and 13 osteoblast genes remained for construction
of PPI networks. For several reasons we found such networks informative. Firstly, they identi-
fied proteins with a large number of interactions and hence hubs that route information. In
osteoclasts, the class 1 gene Ctnnb1 (ß-catenin) formed a central PPI hub (Fig 5C). In addition,
the two class 2 genes Pptc7 and Gtf2a1 served as PPI hubs in these cells. In contrast, in osteo-
blasts we observed that the class 1 gene Col1a2 and to a lesser degree the class 1 gene Plcg2
formed the central PPI hubs (Fig 5D). Secondly, patterns of PPIs uncovered prominent path-
ways in cells. For example, in osteoclasts we discovered a PPI chain connecting Pptc7, Excoc2,
Rab3ip, Arf4, and Ncald (Fig 5C). The latter four proteins, participate in intracellular vesicle
trafficking, highlighting the role of this pathway in BMD control via osteoclast function.
Thirdly, PPI networks detected previously unknown links in BMD pathways. For instance, in
osteoblasts (Fig 5D) the class 2 protein Arl4d interacted with Col1a2 via Kdelr3. Together,
these findings support further investigation of the class 2 genes Pptc7, Rab3ip, Ncald, and
Arl4d, of which the latter three produced a low BMD phenotype upon depletion (Table 1).
The finding that class 2 genes causing low BMD, such as Arl4d, Ncald, and Rab3ip, partici-
pated in osteoclast or osteoblast pathways, raised the possibility that they are involved in the
skeletal mechanisms crucial for maintaining bone mass, particularly bone turnover. In the
absence of established methods that permit rapid testing of potential bone turnover genes,
without the need for animal experimentation, we devised a novel theoretical approach. As
bone resorption and formation underlying bone turnover occur in a spatial and temporal fash-
ion in the extracellular space, we exploited the known key proteins responsible for osteoclastic
resorption of mineralized bone matrix and subsequent osteoblastic matrix formation and min-
eralization. The PPIs between these proteins were recorded and created an in silico bone turn-
over model (Fig 6A). We then introduced the three low BMD class 2 genes Rab3ip, Ncald, and
Arl4d, and found all three genes affiliated with essential extracellular bone turnover proteins
in each case via a single intermediated. The model showed that during extracellular bone
resorption, Rab3ip strongly interacted via Racgap1 with Mmp14 but also with Mmp9 and
Atp6v0d2, suggesting an effect on both bone matrix and mineral degradation (Fig 6B). In con-
trast, Ncald interacted via Fgf2 only with Mmp9 and Mmp14 (Fig 6B), indicating a sole effect
on matrix degradation. With respect to bone formation, Arl4d interacted via Kdelr3 with
Pcolce (Fig 6B), possibly impacting bone matrix assembly. This further supported a role of
Arl4d in osteoblast-mediated BMD maintenance.
Because BMD proteins and their networks are contingent on the transcription of the corre-
sponding BMD genes, we examined whether BMD gene expression was regulated on the
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Fig 5. Subsets of BMD proteins mapped specific pathways in osteoclasts and osteoblasts. Using curated NCBI Gene Expression
Omnibus data, expression of the 200 BMD genes was mapped in (A) osteoclasts, the bone resorbing cells, and (B) osteoblasts, the
bone-forming cells. Protein-protein interactions (PPIs) were identified using the STRING database allowing the annotation of 178
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transcriptional level. Within the pool of the 200 BMD genes, we probed for enrichment of TFs
in promoters of genes causing low compared to high BMD phenotypes upon deletion
(Table 2). A total of 49 and 32 TFs were identified for low and high BMD, respectively. In addi-
tion, we examined the 200 BMD genes for TFs and found 17 and 13 TFs that caused low and
high BMD phenotypes, respectively (S6 Table). Together, these data (1) demonstrated the tran-
scriptional regulation of BMD phenotypes, (2) recognized a total of 127 TFs involved in the
regulation of low and high BMD genes, and (3) discovered 74 TFs that were not reported pre-
viously to be skeletal TFs.
Discussion
On behalf of the IMPC, we have summarized the IMPC skeletal data. The first question this
study addressed was whether screening of mutant mice at scale would identify novel genes
controlling BMD. Phenotyping for BMD was performed on 3,823 mutant mouse strains. Com-
pared to wt controls, we observed altered BMD in 200 mutant strains (Fig 2A). Analysis of this
cohort led to the identification of 141 class 2 genes with a previously unknown function in
controlling BMD (Table 1).
The magnitude of BMD change in response to gene deletion followed a multi-modal distri-
bution (Fig 2C). A high percentage of the 200 BMD genes were associated with a decrease in
BMD between 5% and 10%. Despite the modest decrease in BMD, we consider these genes sig-
nificant, because osteoporosis is believed to be a largely polygenic disorder, determined by the
effects of several genes, each with relatively modest effects on bone mass [22]. Further, we
identified a number of genes producing greater than 10% decreased or increased BMD (Fig
2D and 2E), including novel class 2 genes, for example Nhlh2 and Dppa. A loss of BMD greater
than 20% was recorded for Lepr, Bbs5, Cyp27b1, and Ghrh, while a gain in BMD of more than
20% was only noted for Lrrk1 (Fig 2C–2E and S1 Table). These five class 1 genes are all known
key players in bone biology, and their respective effect on BMD should be considered
confirmatory.
The human relevance of the presented mouse BMD genes was gauged by comparing the
mouse IMPC data to human GWAS data derived from the UK Biobank. An overlap of up to
25% (S3 Table) was seen. Further, a more detailed GWAS analysis based on the GEFOS data
set found that, of the 200 BMD genes, one class 1 and six class 2 genes were linked to corre-
sponding human genes (S4 Table). Together, this showed that mouse-derived BMD data has
relevance for human BMD pathologies, but it also demonstrated that the IMPC mouse data is
complementary to GWAS-derived human data and has the potential for de novo gene discov-
ery. Importantly and in contrast to GWAS studies, the IMPC data is based on targeted gene
disruption, thus potentially offering causal validation of candidate genes found via SNP analy-
sis in GWAS. We anticipate that future progress in the understanding of osteoporosis genetics
hinges on the synergistic application of both human GWAS and the IMPC mouse phenotyping
program. At present, the IMPC BMD data is similar in size to a skeletal phenotyping program
that was carried out between 2000 and 2008 in a commercial setting at Lexicon Pharmaceutical
[23]. However, the IMPC program will continue to grow and thus the skeletal data presented
here will expand in size and depth over time.
of the 200 BMD genes. The central hubs of the network where identified based on the betweenness centrality index and extracted
from the main network. All PPIs were presented as black lines. Blue and yellow nodes represent class 1 (known function in bone
biology) and class 2 genes (unknown function in bone biology), respectively. The zygosity of the mutants is indicated by a
triangular (homozygous) or diamond (heterozygous) shape of the node. The resulting central protein-protein interactions sub-
networks in osteoclasts (C) and osteoblasts (D) are shown. Proteins connecting the BMD gene nodes were represented as small
pink nodes.
https://doi.org/10.1371/journal.pgen.1009190.g005
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Fig 6. An in silico bone turnover model validated class 2 candidate BMD genes. (A) The in silico model of bone turnover captured the extracellular break down of
bone and the subsequent formation of new bone. The model is simplified excluding for example many of the intracellular proteins driving bone turnover or non-
collagenous matrix proteins. While resorption of both bone matrix and mineral may occur concurrent, bone matrix formation typically precedes mineral deposition.
The genes mainly responsible for bone turnover were grouped and annotated as follows. Osteoclastic bone matrix resorption: tartrate-resistant acid phosphatase type
5 (Acp5), essential for osteoclast motility; cathepsin K (Ctsk), matrix break down; matrix metallopeptidase 9, (Mmp9), matrix break down; matrix metallopeptidase 14
(Mmp14), matrix break down. Osteoclastic bone mineral resorption: ATPase H+ transporting V0 subunit D2 (Atp6v0d2), acidic pH and mineral removal; ATPase H
+ transporting V0 subunit A3, (Tcirg1), acidic pH and mineral removal. Osteoblastic bone matrix formation: ADAM metallopeptidase with thrombospondin type 1
motif 2. (Adamts2), N-terminal processing of procollagen; ADAM metallopeptidase with thrombospondin type 1 motif 14 (Adamts14), N-terminal processing of
procollagen; bone morphogenic protein 1 (Bmp1), C-terminal processing of procollagen; collagen type I alpha 1 chain (Col1a1) and collagen type I alpha 2 chain
(Col1a2), procollagen formation; procollagen C-endopeptidase enhancer 1 (Pcolce), enhancer of C-terminal processing of procollagen; tolloid like 1 (Tll1), C-terminal
processing of procollagen. Osteoblastic bone mineral deposition: tissue-nonspecific alkaline phosphatase (Alpl), removal of mineralization inhibitor inorganic
pyrophosphate (PPi); ectonucleotide pyrophosphatase/phosphodiesterase 1 (Enpp1), production of PPi. Together, these proteins (red elliptic nodes) formed the PPI
networks for osteoclastic resorption and osteoblastic formation during bone turnover. Connecting proteins distinct from the bone turnover genes are represented as
pink elliptic nodes, while white nodes marked genes with an undefined role in bone. Black lines represent PPIs as determined by STRING or REACTOME analysis.
Arrows indicated REACTOME-curated data. For validation, we used experimental gene expression data from osteoclasts and osteoblasts in combination with
statistical testing. The resulting gaussian probability of interactions, i.e. FDR-adjusted p-values (q-values) were superimposed on the STRING PPIs as follows: large
line width, q<0.0005; medium line width, q<0.05; small line width, q>0.05 or no q data. (B) Based on their cellular expression, the three class 2 low BMD candidate
genes Rab31p, Ncald, and Arl4d were probed in the osteoclastic and osteoblastic compartments of bone turnover. Rab3ip and Ncald interacted via single
intermediates with proteins degrading bone matrix and also mineral, while Arl4d, also via an intermediate, interacted with a regulator of the procollagen cleavage
essential for bone matrix formation.
https://doi.org/10.1371/journal.pgen.1009190.g006
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Table 2. TFs enriched in low or high BMD genes (i-CisTarget analysis).
Low BMD High BMD
TF NES BMD Genes STF TF NES BMD Genes STF
Class 1 Class 2 Total Class 1 Class 2 Total
1 Bnc1 4.516 3 11 14 Yes Maz 5.739 7 4 11 Yes
2 Mxi1 4.513 16 45 61 Yes Scrt2 4.334 5 9 14 No
3 Tga2 4.427 4 9 13 No Hif1a,Arnt 4.219 5 3 8 Yes
4 Creb3l1 4.400 10 19 29 Yes Caco2 4.198 6 4 10 No
5 Hcfc1 4.028 7 17 34 No Foxd1 4.016 8 6 14 Yes
6 Fbp6 3.866 2 13 15 No Hif1a 3.861 12 14 26 Yes
7 Zfp260 3.839 2 14 16 No Bach1 3.838 6 6 12 No
8 Polr2a 3.793 18 56 74 No Xbp1p 3.668 4 4 8 No
9 Nac6 3.727 5 8 13 No Madf 3.667 7 11 18 Yes
10 Foxo4 3.718 6 10 16 Yes Nf1 3.605 6 5 11 No
11 Mads3 3.717 6 13 19 No Bhlhe40 3.552 6 4 10 No
12 Zmiz1 3.652 7 7 14 No Hes2,Hes5 3.487 3 9 12 Yes
13 Zfp1 3.621 5 12 17 No Srf,Rfx3 3.407 5 7 12 Yes
14 Ascl2,ascl1 3.565 5 12 17 Yes zf-C2H2 3.349 5 8 13 No
15 Hlf 3.505 6 9 15 No Evx2 3.333 4 5 9 Yes
16 Zfp92 3.436 6 6 12 No Evx1 3.319 4 5 9 Yes
17 Zbtb33 3.411 24 62 86 Yes Zfp62 3.307 5 7 12 No
18 Hy5 3.389 6 9 15 No Rbak 3.295 4 3 7 No
19 Ets1 3.388 7 8 15 Yes Zfp667 3.286 7 7 14 No
20 At4g28140 3.354 4 9 13 No Klf11 3.279 15 18 33 No
21 Jun 3.348 5 18 23 Yes Klf10 3.270 15 18 33 Yes
22 Jund 3.330 2 9 11 Yes Klf13 3.270 13 18 31 No
23 Gbf1 3.328 4 9 13 No Zbtb7c 3.259 16 28 34 No
24 Cej1 3.324 1 9 10 No Srebf1 3.232 5 6 11 Yes
25 Rap2 3.300 5 10 15 No Bteb1 3.162 14 18 32 No
26 Yy1 3.292 5 12 17 Yes Sall2 3.155 6 7 13 No
27 Mads26 3.287 5 13 18 No Znf224 3.114 5 7 12 No
28 Tavrt-1 3.284 6 11 17 No Tbx3,Hoxb13 3.051 5 3 8 Yes
29 Eomes 3.261 3 6 9 Yes Tfeb 3.044 5 5 10 Yes
30 Mads11 3.255 8 11 19 No Zrsr2 3.043 6 5 11 No
31 Opaque-2 3.252 9 15 24 No Pitx1,Hoxa3 3.020 6 5 11 Yes
32 E2f6,nr3c1 3.240 6 11 17 Yes Cbf1 3.013 7 6 13 Yes
33 Erf,nhlh1 3.230 4 7 11 Yes
34 Foxo1,elk1 3.197 3 11 14 Yes
35 Nfil3 3.171 16 42 58 Yes
36 Sin3a 3.151 7 20 27 Yes
37 Znf418 3.146 13 29 42 No
38 Fbp21 3.142 8 12 20 No
39 Foxo1,fli1 3.138 1 10 11 Yes
40 Ets1,tfap4 3.121 4 15 19 No
41 Xbp1 3.104 4 11 15 Yes
42 Zfp408 3.086 3 11 14 No
43 Mads2 3.086 5 11 16 No
44 Elf1,foxo1 3.083 3 11 14 No
45 Nr2e1 3.063 5 16 21 No
46 Myc 3.057 4 5 9 Yes
47 Cbt 3.038 3 8 11 Yes
48 Znf256 3.025 5 15 20 No
49 Creb3l2 3.002 5 5 10 Yes
Abbreviations: BMD, bone mineral density; NES, enrichment score; STF, known skeletal TF; TF, transcription factor.
https://doi.org/10.1371/journal.pgen.1009190.t002
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A gender-specific action of BMD genes has been postulated previously but led to inconclusive
results. On the one hand, a recent GWAS study dedicated to the assessment of gene-by-sex inter-
action, did not find such an interaction for BMD [24]. On the other hand, a string of earlier stud-
ies using whole genome quantitative trait loci analyses identified chromosomal regions linked to
sex-dependent regulation of BMD [25–27]. Further, studies using individual gene deletion in
mice, proved that genes cause gender-restricted effects on BMD [28]. Lastly, it has been shown
that the regulation of a gene can vary between the sexes [29]. In the present study, which we
believe is currently the most comprehensive analysis reporting BMD changes in both male and
female mutant mice, we defined 90 genes that, upon deletion, caused a change in BMD that was
restricted to either female or male animals (Fig 3A–3C). Notably, in females the number of
genes causing low BMD was about 4-fold greater than the number of genes producing high
BMD (Fig 3A and 3B). In contrast, in males a comparable number of genes were associated with
low and high BMD (Fig 3A and 3B). The reason of this distribution is currently unknown. Pre-
liminary annotation of the 90 genes identified most frequently energy metabolism pathways (S7
Table) and was not restricted to hormonal pathways known to affect bone [30]. Together, our
data further supports the hypothesis of sexual dimorphism in BMD gene regulation.
The 200 BMD genes discussed above, included 59 class 1 genes. Although these class 1 gene
have a known function in bone biology, our study revealed a previously unknown function in
BMD control for about half of the 59 genes (S8 Table), and we plan on further investigating
these BMD genes in separate studies. Another important aspect of the class 1 gene set is that it
offered an opportunity to validate the presented large-scale phenotyping approach. Comparing
our BMD data to previously published reports, we found an agreement for 57 out of 59 genes
or 95% (S8 Table). Given that large scale mouse screenings use a highly pre-defined analysis
pipeline with little option for tailored analysis or cell biology studies, we felt an error rate of
5% supported the robustness of the presented data. A clear discrepancy between our findings
and previous data was seen for two genes. First, Ndrg1, a ubiquitously expressed protein with
unclear cellular function. Deletion of his gene was previously reported by Watari et al. on a B6
background and produced animals of short stature that exhibited neurological and skeletal
abnormalities, including spinal curvature and an at least 60% increase in BMD [31]. The
IMPC model reported here matched those phenotypes with the exception that we did not
record spinal changes and observed a<5% decrease in BMD. These differences may result
from different gene targeting strategies or skeletal analyses. For example, Watari et al.
employed in vitro microCT analyses, while we used in vivo DXA. Further, Watari et al. mea-
sured volumetric BMD on the femur and we reported areal BMD across the skeleton, exclud-
ing the skull. A second gene with conflicting results was Col1a2. This gene codes for the
collagen type I alpha 2 chain, which together with the collagen type I alpha 1 chain, form het-
ero-trimeric procollagen. We were surprise to measure a slightly increased BMD in Col1a2
deficient mice. Loss of Col1a2 in mice has been studied previously [32]. For example, in the
osteogenesis imperfecta murine (oim) model, a single nucleotide deletion in the Col1a2 gene,
resulted in a normal size mRNA, but fail to secrete the protein. Bones in these mice are com-
posed of Col1a1 chains only, forming homo-trimeric type 1 collagen. Phillips et al. reported
reduced BMD in oim mice based on DXA measures. In line with these findings, the Amish
Col1a2 mouse model exhibited reduced BMD across several genetic backgrounds [33]. Fur-
ther, homo-trimers due to COL1A2 mutations have been reported in patients and manifested
in forms of osteogenesis imperfecta or Ehlers-Danlos syndrome [34]. In some patients, BMD
was measured and generally found to be decreased [35–37]. Interestingly, mutations that spe-
cifically affect the C-propetide cleavage site of COL1A2 result in high BMD [38]. Taken
together, previous data from mice and humans let us to expect a decreased rather than
increased BMD as a result of Col1a2 deletion in mice. Hence, for our Col1a2 mutant in
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particular, the inherent limitation of large-scale phenotyping became apparent because molec-
ular and cell biology studies are essential to verify the expected mRNA status and collagen tri-
mer composition. The comprehensive dataset we reported in this study also included 3,623
genes that upon deletion did not show a significant BMD phenotype (S2 Table). A preliminary
assessment of these genes showed that the false negative rate was about 2%, further supporting
the robustness of our data (S2 Table). Within the pool of BMD negative genes, two genes illus-
trated principle restrictions in our approach. First, we did not detect a change in BMD upon
deletion of Daam2. Yet, using GWAS for both BMD and bone fracture as well as mouse and in
vitro studies, Morris et al. identified Daam2 as a potential genetic factor in osteoporosis [10].
In fact, they investigated the same Daam2 KO mouse as we did, however they relied on the
OBCD pipeline for skeletal analyses. Consistent with our findings, no BMD alteration was
seen, but bones of KO mice showed reduced mechanical stability. This example highlights the
previously discussed limitation of sole BMD measures for the detection of osteoporosis genes
[39]. Second, based on the IMPC data release 6.0, which we explored in this study, we observed
no BMD phenotype after deletion of Slc20A2. However, the ongoing IMPC program con-
stantly adds data on new mouse KO lines, and thus over time the pool of control mice may
expand or changes to the PhenStat statistical package introduced. This can affect data output.
In fact, in IMPC data release 11 the gene Slc20A2 has been assigned a BMD phenotype. From
a comparison between different IMPC data releases, we estimate that such shifts in BMD phe-
notype hits may occur in the order of 0.5% of genes per release. Regardless, we recommend
that investigators interested in skeletal studies using IMPC mouse models (a) re-examine the
mutant mice and matching wt controls using in vivo DXA and standard laboratory and animal
group sizes, and (b) perform in vitro microCT at least including parameters measured under
the OBCD pipeline, such as femur bone volume/tissue volume, BMC, and BMD as well as sev-
eral structural measures derived from cancellous and cortical bone.
The 141 class 2 genes constitute an important stand-alone data set, as they provide experi-
mental in vivo evidence justifying the molecular and cellular investigation of a comparably
large number of gene products previously not known to affect BMD. In this study, however,
we sought to address further questions. We asked which of the 200 BMD genes caused both
BMD alterations and skeletal abnormalities. A set of 19 class 2 genes was found (Fig 4C). To
assess a potentially compromised skeletal stability in mice lacking one of these genes, we initi-
ated and executed the import of data from the OBCD program into IMPC, a step necessary for
proper data analysis. Despite the currently limited overlap (around 10%) of genes in the IMPC
and OBCD programs, Hbs1l could be analyzed and was found to yield an altered, reduced
skeletal stability after ablation. This is an important finding because bone fragility is a hallmark
of osteoporosis. However, loss of Hbs1l, which codes for a GTP-binding elongation factor,
yields several co-phenotypes and thus further examination of tissue-specific functions of
Hbs1l is needed. Noteworthy, a brief report previously described the occurrence of a Hbs1l
mutation in humans [40], and the IMPC knockout mouse model is currently used to further
investigate Hbsl1 loss [41]. Independent of the OBCD program, we considered more general
criteria useful for the identification of promising new BMD genes. Arguably, we used a limited
weight loss and low number of co-phenotypes as indicators for a direct skeletal action of a
gene. The six genes, Arl4d, Sdsl, Bbx, Fam160a1, Pld5, and Tnfaip1, scored with both limited
body weight alteration and low pleiotrophy.
Another question we asked was whether evidence existed for functions of BMD genes in
osteoclasts or osteoblasts. Our experimental approach was to use available gene expression
data for assignment of the 200 BMD genes to osteoclasts and osteoblasts. For high confidence,
curated data acquired during bone cell differentiation was used. We utilized this data for two
purposes. First, we simply probed for cellular expression (Fig 5). Here, we noted that several
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class 1 osteoclast genes, like Ckb, Ndrg1 and Sat1b, were also detected in osteoblasts (Fig 5).
Because of a lack of verification of their biological function in osteoblasts, we did not further
consider these genes. Second, gene expression data was included in the more sophisticated cal-
culations of protein interaction probabilities (Fig 6). Concerning both uses, we emphasize that
expression data depends on biological factors, including cell type and time-point investigated,
and may only present a snapshot of a biological system. With these limitations in mind, we
assigned the BMD genes to osteoclasts and osteoblasts and surveyed for protein-protein inter-
actions using STRING (Fig 5). Because the action of genes occurs on the protein level, testing
for protein-protein interactions has merit. STRING also provides an opportunity to investigate
gene products lacking extensive prior characterization. Despite these advantages, our
STRING-based analyses had two principle limitations. Firstly, the interactions shown in the
networks comprised a range of interaction modes, which were not always experimentally veri-
fied. Secondly, in addition to the BMD genes identified in this study, the networks incorpo-
rated gene products that do not have an experimentally confirmed role in bone cells.
Regardless, several genes with a known function in bone cells (class 1), such as Ctnnb1 [42,
43], were detected and validated our approach.
With respect to proteins previously not noted to have a function in bone biology (class 2),
we report several intriguing findings. In osteoclasts, STRING mapped the protein phosphatase
Pptc7 which has a clear function in CoQ10 biosynthesis [44], a biochemical pathway with an
established role in osteoclasts [45]. However, Pptc7 is also localized in the plasma membrane
(PM) and STRING predicted an interaction of Pptc7 with the guanine nucleotide exchange
factor Rab3ip via Exoc2, a component of the exocyst complex. Rab3ip is a class 2 protein with
a known function in vesicle transport and together with Exoc2 may mediate transport to the
plasma membrane and thus may participate in the vesicle transport of Pptc7 to the PM [46].
STRING analysis also demonstrated an interaction of Rab3ip with the ADP-ribosyltransferase
Arf4. Like Rab3ip, the Arf-family of small GTPase, including Arf4, functions in vesicle traffick-
ing [47]. Moreover, an interaction of Arf4 with the class 2 gene Ncald was found. Ncald is a
regulator of G-protein receptor signaling and has a function in calthrin-coated vesicle trans-
port [48]. Importantly, data has suggested that clathrin-coated vesicle transport plays a role in
osteoclasts [49]. Together, the class 2 genes Rab3ip and Ncald, which both cause low BMD
upon deletion (Table 1), are likely to participate in vesicle trafficking in osteoclasts, supporting
the emerging role of membrane trafficking in bone biology and pathology [49]. Regarding
osteoblasts, STRING mapped the Arf-like (Arl)4d protein, which upon deletion caused both
low BMD (Table 1) and skeletal abnormalities. i.e, abnormal rib morphology (Fig 4C). It fur-
ther proposed an interaction of Arl4d with the KDEL endoplasmic reticulum protein retention
receptor 3 (Kdelr3), and also a Kdelr3 interaction with Col1A2. The latter is a major compo-
nent of the bone matrix and is synthesized, heterodimerized with Col1A1, and secreted as pro-
collagen. The underlying secretory pathways are not fully elucidated but appears to include
secretory vesicles/granules tailored to the rigid and bulky procollagen load [50]. The interac-
tion of Kdelr3 with Col2a1 is likely based on the prominent function of the KDEL receptors in
cis-Golgi sorting and recycling of KDEL-tagged proteins, such as the collagen-specific chap-
eron Hsp47 [51]. The interaction of KDEL receptors with Arl4d, however, might be different
from their interaction with collagen. Data has shown that KDEL receptors control the recruit-
ment of cytosolic GTPase activating proteins (GAPs) to plasma membrane (PM)-bound Arfs
[52]. As GTPases, Arfs are not only regulated by GAPs, but also guanine nucleotide exchange
factors (GEFs), necessitating GEF recruitment to the PM. Studies have reported localization of
Arl4d to the PM where it functions to recruit cytohesins, including the GEF ARNO. This GEF
controls Arf6, which is a known regulator of endocytotic traffic, but also exocytotic granule
transport [53]. Therefore, the study presented here led to the working hypothesis that in
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osteoblasts loss of Arl4D compromises the exocytotic vesicle transport of bone ECM compo-
nents. The above findings were supported by interpretation of the in silico bone turnover
model (detailed in S1 Text), which let us to speculate that (a) Rab1ip acts through Rab8b and
Rho signaling, (b) Ncald, in the presence of FGF-2, engages with guanylyl cyclase-B, and (c)
Arl4d is involved in the exocytotic vesicle-based secretion of Pcolce. We emphasize that the in
silico bone turnover model at present has a limited and biased selection of genes and needs
experimental validation. It may, however, prove useful for other large-scale genetic studies on
bone for three reasons. First, it is compatible with gene sets from a variety of sources and spe-
cies. Second, it can be easily recreated by other laboratories at no cost. Lastly, the model is
expandable to include additional genes and tailorable to specific research questions.
Taken together, this study (1) identified and characterized BMD genes, including 141 class
2 genes that lacked prior association with bone biology, (2) prioritized the class 2 genes based
on magnitude of BMD change, human relevance, or pleiotropy, (3) offered cues on pathways,
such as vesicle transport, governing bone cell biology in BMD pathologies, and (4) under-




All animal work described in this study was carried under the auspice of approved animal pro-
tocols (Baylor College of Medicine, #AN-5896; German Mouse Clinic Helmholtz Zentrum
München, #144–10, 15–168; Institut Clinique de la Souris Mouse Clinical Institute, #4789-
2016040511578546v2; Medical Research Council Harwell, #30/3384; Nanjing University,
#NRCMM9; Rikagaku Kenkyūjo Tsukuba Institute, #Exp11-011, 12–011, 13–011, 14–009, 14–
017, 15–009, 16–008; The Centre for Phenogenomics, #0153, 0275, 0277, 0279; The Jackson
Laboratory, #11005).
Generation of mutant mouse strains
The IMPC systematically phenotypes mice that are homozygous for a single-gene knockout
or heterozygous when homozygotes are lethal or sub-viable. IMPC members and non-mem-
bers are free to nominate genes for deletion, and mouse production was coordinated by iMits
(Fig 1A). The gene-targeting strategies that are used can be accessed via http://www.
mousephenotype.org/about-ikmc/targeting-strategies. For every IMPC deleted gene, specifics
on the targeting strategy can be obtained through a gene search on the IMPC website (http://
www.mousephenotype.org) and use of the “Order Mouse and ES Cells” tab. In the case of sin-
gle copy genes, hemizygous knockout mice are studied. IMPC mouse models are available to
the research community via the IMPC website.
Mouse phenotyping
Data was derived from postnatal mice that were phenotyped under the adult and embryonic
phenotype pipeline (https://www.mousephenotype.org/impress). Briefly, this pipeline con-
ducted 16 tests, each with a set of phenotyping procedures. Phenotyping recorded appearance,
behavior, or organ function across a spectrum of organs and tissues. All IMPC phenotyping
data is shared with the public through the IMPC website. Experimental procedures are detailed
also under IMPRESS (https://www.mousephenotype.org/impress). Although we mined the
entire phenotyping data when investigating co-phenotypes, our study primarily investigated
the X-ray phenotyping data obtained in postnatal week 14. The skeletal X-ray exams
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encompass radiographs and DXA-based measures of BA and BMC. Radiography and DXA
are mandatory and voluntary IMPC measures, respectively. Specifically, for the data reported
in this study, they were carried out using the UltraFocus DXA (Faxitron Bioptics LLC), the
Lunar Piximus II (GE Medical Systems), or the pDexa sabre (Norland Stratec) instruments.
For DXA, a minimum of 7 male and 7 female mutants were phenotyped, giving a minimum
of 14 mice per line, while for radiography phenotyping was performed on a minimum of 4
male and 4 female mutants. In all experiments, mutants were matched with wild-type (wt) ani-
mals, with matching genetic background. Mutant and wt mice were phenotyped in the same
manner based on the IMPReSS protocol, and detailed experiment characteristics captured in
the procedure metadata. BMD was calculated from the measures of BA and BMC. For data
analysis, mutants were matched with wt animals from the same center that used the same
metadata.
IMPC data analysis
The IMPC uses a bespoke statistical package, implemented in R, called PhenStat, which was
developed for identification of abnormal phenotypes from high-throughput pipelines [54].
The bone mineral data was analyzed by PhenStat using linear, mixed models, which take fac-
tors such as sex and body weight into account. S1 Table details the number of wt control mice
analyzed for each of the 200 BMD genes. PhenStat identifies phenotype hits by sex to enable
identification of sex-specific phenotypes which have been previously shown to be relevant in a
large proportion of IMPC lines across many procedures [17].
Phenotype hits were identified by searching the IMPC database (version 6.0, released
November 10th, 2017, data access: https://www.mousephenotype.org/data/previous-releases/6.
0) for Mammalian Phenotype (MP) terms as listed in IMPReSS. For bone mineral density, that
includes the terms Increased Bone Mineral Density (MP:0000062) and Decreased Bone Min-
eral Density (MP:0000063). For those lines found to have BMD phenotypes, radiography-
related MP terms, as listed in the IMPReSS X-ray procedure, were also queried to identify any
skeletal phenotypes (www.mousephenotype.org/impress/procedureontologies/91/7).
Gene classification and assessment of sexual dimorphism
To learn more about the BMD phenotype genes and to classify genes as known or unknown to
be associated with bone PubMed was searched using the gene names along with the search
terms “osteoblast”, “osteoclast”, “osteocyte”, “osteogenic”, “skeletal” and “bone” NOT “bone
marrow”. These broad terms were selected empirically to cover a wide range of bone biology.
We also repeated the same searches, but with the inclusion of “mouse” and “human”. Our
search did not encompass other skeletal tissues such as mesenchymal stem cells, cartilage, den-
tal tissues, or malignancies. The literature search was closed on June 16, 2018.
Genes controlling BMD in a sex-biased fashion were retrieved from the 200 BMD pheno-
type genes. MGI and GeneCards were used to identify the chromosomal localization of genes
in mice and humans, respectively. To identify genes described previously in the context of sex-
ual dimorphism we used PubMed in combination with the search terms “sexual dimorphism”,
“sexual”, “sex”, “male AND female”.
Mapping genes to gene ontology terms
GO terms for the genes of interest were extracted from the MGI database (www.informatics.jax.
org), which contains information on genes and their annotated phenotypes. In order to avoid cir-
cular findings, as the MGI database includes IMPC phenotype data, IMPC entries were removed
using MGI’s internal filters. We analyzed terms of the “molecular function” and “biological
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processes” domains as they provide information on the biological activity of genes of interest. To
identify genes involved in skeletal function based on gene ontology term annotation, we selected
all gene ontologies that included the terms “bone”, “skeletal”, “ossification”, “osteoclast” and “oste-
oblast”. MGI’s Gene eXpression Database www.informatics.jax.org/expression.shtml) was also
searched to determine the known expression profiles of the BMD phenotype genes.
Genome-wide association studies (GWAS)
Orthologous/paralogous genes of mouse metabolism genes mapping to the human genome
were used for analysis. GWAS analyses on human BMD were based on data acquired in the
UK Biobank (www.ukbiobank.ac.uk) [9, 10, 55] and GEFOS (www.gefos.org) [8] studies. We
used the Ensembl BioMart online tool to adjust all genomic data to the latest Assembly
(GRCh38/hg38). The UCSC genome browser was used to analyze genes in detail. We searched
for SNPs in a ±2 kb region in the SNiPA database. For each SNP occurring in or around genes,
we evaluated the extent of sharing based on the three bone density phenotypes recorded by the
GEFOS consortium, and used metadata without any link to individual IDs or data only. We
used cross phenotype meta-analysis (CPMA), which detects association of a SNP to multiple,
but not necessarily all, phenotypes [56]. The CPMA analysis applies the likelihood ratio test
that measures the likelihood of the null hypothesis (i.e., that the significant SNP is uniformly
distributed across consortiums) over the alternative hypothesis.
OBCD data
The OBCD (www.boneandcartilage.com) is a project performing bone and cartilage-related
phenotyping on knockout mouse models. The bone-based procedures performed include
three-point bend and vertebra compression, for which they currently have data for a total of
410 lines. These procedures were carried out in female animals only. In male animals, rapid-
throughput joint phenotyping was performed instead. Analysis of the female OBCD bone data
set was based on a tight reference data obtained from a population of>300 strain-matched
female wt mice, giving it the power to detect differences between controls and small cohorts
(two female animals per line) of mutant mice [5, 9, 57]. To identify lines with data differing
from the wt, those with measurements greater than two standard deviations from the wt mean
were considered significant.
Gene expression analysis
The NCBI Gene Expression Omnibus was used to analyze gene expression in osteoblasts and oste-
oclasts. To assure robustness of the expression data, the analysis was restricted to the curated data
available under https://www.ncbi.nlm.nih.gov/sites/GDSbrowser/, and only data on mouse-derived
cells was considered. To identify genes expressed in osteoclasts or osteoblasts, we assessed expres-
sion data acquired during differentiation of these cells. Genes significantly (p<0.05) increased dur-
ing differentiation were considered. For osteoclastogenesis, data sets GSE43811 and GSE57468
(series GDS5398 and GDS5422, respectively) were used. GSE43811 compared osteoclast differenti-
ation at 48 hrs between osteoclast precursor cells (GSM 1071626, 1071627, 1071628) and control
cells (GSM 1071629, 1071630, 1071631). In Additionally, we selected GSE57468, which compared
differentiation of primary osteoclast precursors between days 0 (GSM1383260, 1383262) and 3
(GSM1383261, 1383263). For osteoblastogenesis, the data set GSE2332 (series GDS1631) was
selected because it permitted for the study of highly enriched primary pre-osteoblasts. Differentia-
tion days 7 (GSM43188, 43202, 43209) and 17 (GSM43195, 43216, 43225) were included. All data
was analyzed using the dedicated NCBI Geo2R suite (https://www.ncbi.nlm.nih.gov/geo/geo2r/).
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Examination of protein-protein interaction (PPI) networks and the in silico
bone turnover model
All PPI networks were built in STRING DB (https://string-db.org/). The proteins coded by the
200 BMD genes served as input or “seeds”. Our analysis utilized minimum networks generated by
NetworkAnalyst. Based on the “String04 all sources” mode, up to 86% of the seeds were annotated
(172 BMD proteins) with at least one PPI. Using these networks we calculated different centrality
indexes using the cytoHubba app in Cytoscape to identify hubs central for maintaining the com-
munication flow on the different parts of the network. To assess the significance of the network, it
was then tested for the likelihood of observing a network with a the same degree of connectivity
by comparing the reciprocity of the network versus 100,000 simulated networks of the same
degree using the statnet and sna R packages (https://cran.r-project.org/web/packages/statnet/
index.html, https://cran.r-project.org/web/packages/sna/index.html). For combined analysis of
BMD proteins and TFs, the yfiles layouts were employed in Cytoscape. The radial layout algo-
rithm was chosen. It portraits interconnected ring and star topologies. This algorithm produces
layouts that emphasize sub-groups and tree structures within a network. It creates node partitions
by analyzing the connectivity structure of the network and arranges the partitions as separate cir-
cles or disks. To develop networks representing an in silico bone turnover model, we used clinical
markers of bone turnover as a guide for the identification of the most established proteins partici-
pating in bone turnover [58, 59]. Our final selection of bone turnover genes was supported by
published data [60–62]. To experimentally validate the in silico model, we used gene expression
data together with the R package GeneNet 1.2.13 (http://www.strimmerlab.org/software/genenet/
). Based on gene expression data this package enabled the statistical assessment of the reliability of
a given network (nodes and edges) and to compute q-values and posterior probabilities (= 1-local
FDR) for each potential edge connecting in a pairwise manner the nodes of the network (S9
Table). We captured the bone resorption-formation sequence characteristic for bone turnover
with the following expression data sets (1) GSE43811 (GSM 1071626, 1071627, 1071628 and GSM
1071629, 1071630, 1071631), (2) GSE57468 (GSM1383261, 1383263 and GSM1383260, 1383262),
(3) GSE2332 (GSM 43191, 43212, 43219 and GSM 43184, 43205, 431198), (4) GSE37676 (GSM
25432, 25433, 25434 and GSM 25429, 25430, 25431), (5) GSE2332 (GSM43195, 43216, 43225 and
GSM43188, 43202, 43209). The normalized log2FC expression values (GSE158151) from these
datasets were used as input files for GeneNet [63].
Promoter analysis
To identify TFs that may regulate genes implicated in bone phenotypes, we surveyed for the
bone transcriptional targets, which contain common TF binding sites in their cis-regulatory
control elements. Using i-CisTarget and two datasets as input; genes with increased bone min-
eral density and genes with decreased bone mineral density, we detected motifs within 10Kb
around the transcription start site. Every gene was scanned for motifs using a library of approx.
10k PWMs and 1120 Chip-seq tracks, each motif is scored with an algorithm called Cluster-
buster and results in a subset of genes that are predicted as direct targets.
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